Format
Items per page

Send to:

Choose Destination

Links from PubMed

Items: 6

1.

Factor VIII product

Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. [from MeSH]

MedGen UID:
41952
Concept ID:
C0015506
Amino Acid, Peptide, or Protein; Biologically Active Substance; Pharmacologic Substance
2.

Humate-P

MedGen UID:
39438
Concept ID:
C0086428
Amino Acid, Peptide, or Protein; Pharmacologic Substance
3.

von Willebrand factor

A high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor VIII/von Willebrand factor complex. The von Willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. It functions in adhesion of platelets to collagen and hemostatic plug formation. The prolonged bleeding time in VON WILLEBRAND DISEASES is due to the deficiency of this factor. [from MeSH]

MedGen UID:
22685
Concept ID:
C0042971
Amino Acid, Peptide, or Protein; Biologically Active Substance; Pharmacologic Substance
4.

Von Willebrand Factor Human

von Willebrand factor (2813 aa, ~309 kDa) is encoded by the human VWF gene. This protein is involved in platelet adhesion and blood coagulation. [from NCI]

MedGen UID:
473301
Concept ID:
C0795677
Amino Acid, Peptide, or Protein; Biologically Active Substance; Pharmacologic Substance
5.

von Willebrand disorder

Von Willebrand disease (VWD), a congenital bleeding disorder caused by deficient or defective plasma von Willebrand factor (VWF), may only become apparent on hemostatic challenge, and bleeding history may become more apparent with increasing age. Recent guidelines on VWD have recommended taking a VWF level of 30 or 40 IU/dL as a cut-off for those diagnosed with the disorder. Individuals with VWF levels greater than 30 IU/dL and lower than 50 IU/dL can be described as having a risk factor for bleeding. This change in guidelines significantly alters the proportion of individuals with each disease type. Type 1 VWD (~30% of VWD) typically manifests as mild mucocutaneous bleeding. Type 2 VWD accounts for approximately 60% of VWD. Type 2 subtypes include: Type 2A, which usually manifests as mild-to-moderate mucocutaneous bleeding; Type 2B, which typically manifests as mild-to-moderate mucocutaneous bleeding that can include thrombocytopenia that worsens in certain circumstances; Type 2M, which typically manifests as mild-moderate mucocutaneous bleeding; Type 2N, which can manifest as excessive bleeding with surgery and mimics mild hemophilia A. Type 3 VWD (<10% of VWD) manifests with severe mucocutaneous and musculoskeletal bleeding. [from GeneReviews]

MedGen UID:
22686
Concept ID:
C0042974
Disease or Syndrome
6.

Desmopressin acetate

An analogue of the hormone vasopressin with antidiuretic and antihemorrhagic properties. Desmopressin acetate has selective affinity for the V2 receptor and acts on the distal kidney tubule by increasing the cellular permeability thereby stimulating water reabsorption. This antidiuretic agent is used in the treatment of central diabetes insipidus. An unrelated action of desmopressin acetate is to increases circulating factor VIII and is used in patients with haemophilia and von Willebrand's disease. [from NCI]

MedGen UID:
39171
Concept ID:
C0086135
Amino Acid, Peptide, or Protein; Hormone; Pharmacologic Substance
Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center